In The News: School of Integrated Health Sciences
In the US, about 6.2 million people have Alzheimer's disease. ҳ| 鶹ýӳ 70% experience agitation — extreme emotional distress that can manifest as resisting care, shouting, or becoming physically violent — and 40% have symptoms severe enough to require treatment, Dr. Jeffrey Cummings told Insider. But there isn't a single approved drug to treat agitation in people with Alzheimer's.
Dr. Kara Radzak interviews Dr. Sandy Shultz, Dr. Lindsey Lepley, and Dr. Shelby Baez about the work investigating ACL injury risk and rehabilitation strategies for patients with ACL reconstruction. This interview is accompanying the release of a special issue of the Journal of Athletic Training women who are scholars in athletic training research.
The theme song of an ’80s sitcom goes, “You take the good, you take the bad/You take them both and there you have/The facts of life.” The same can be said of our gut microbiome, the complex system—comprising 300 to 500 species of good and bad bacteria—that affects not just our digestive system but also has links to mental health, autoimmune diseases, endocrine disorders, cancer and more.
The pandemic has done a number on our stomachs. We’re mostly stuck at home—whether working remotely or just staying safe in quarantine. And it’s too easy to just snack all day.
Can certain foods kick your body’s metabolism into a higher gear to help you lose weight? Many foods are touted as metabolism boosters, but how much and when you eat may be more effective ways to get the most impact from your workouts.
What foods help you fuel your workouts, and what should you eat after physical activity?
Last week, AB Science reported successful results from a phase IIb/III clinical trial testing its drug masitinib in patients with mild to moderate symptoms of Alzheimer’s.
AB Science SA (NYSE Euronext – FR0010557264 – AB) will host a live webcast on December 17, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in Alzheimer’s Disease.
AB Science SA (NYSE Euronext – FR0010557264 – AB) will host a live webcast on December 17, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in Alzheimer’s Disease.
A little more than a century ago, a German psychiatrist and neuropathologist by the name of Aloysius Alzheimer, MD, first described the pathology and symptoms of a disease known as presenile dementia at a 1906 meeting of the Southwest German Psychiatrists.
An all-star panel of experts on women’s brain health and wellness led a 90-minute virtual event viewed by more than a thousand people on Dec. 3.
Will Biogen’s aducanumab become the first drug approved to slow progression of Alzheimer’s disease? Biogen’s licensing application for the biologic ran into headwinds at a U.S. Food and Drug Administration advisory committee meeting held November 6. It was led by the agency’s Billy Dunn, who directs development of new neurology treatments (Nov 2020 news). The agency’s internal biostatistical and neurologic reviews presented starkly opposing views of the efficacy data—the former critical, the latter glowing. This disconnect consternated both the committee and the many scientists listening to the public proceedings from around the country.